• 首页期刊简介编委会刊物订阅专栏专刊电子刊广告合作联系我们English
引用本文:陈燕,张雅雯,周云琍,陈晓晓,王胜浩,尹丽娜.响应面法优化西罗莫司胶束及其促小肠吸收作用[J].中国现代应用药学,2020,37(8):939-944.
CHEN Yan,ZHANG Yawen,ZHOU Yunli,CHEN Xiaoxiao,WANG Shenghao,YIN Lina.Optimization of Sirolimus Micelles by Response Surface Methodology and Its Effect on Small Intestinal Absorption[J].Chin J Mod Appl Pharm(中国现代应用药学),2020,37(8):939-944.
【打印本页】   【HTML】   【下载PDF全文】   查看/发表评论  【EndNote】   【RefMan】   【BibTex】
←前一篇|后一篇→ 过刊浏览    高级检索
本文已被:浏览 1492次   下载 763 本文二维码信息
码上扫一扫!
分享到: 微信 更多
响应面法优化西罗莫司胶束及其促小肠吸收作用
陈燕1, 张雅雯2, 周云琍1, 陈晓晓1, 王胜浩3, 尹丽娜2
1.浙江中医药大学药学院, 杭州 310053;2.杭州医学院药物研究所, 杭州 310013;3.浙江中肽生化有限公司, 杭州 310018
摘要:
目的 制备和优化西罗莫司(sirolimus,SRL)聚合物胶束,考察其对大鼠在体肠吸收动力学的影响。方法 以去氧胆酸修饰的壳聚糖(deoxycholic acid grafted chitosan,CS-DCA)为载体,采用溶剂蒸发法制备SRL CS-DCA胶束。以包封率、载药量、粒径和电位作为考察指标,结合星点设计-效应面法优化处方。建立大鼠在体单向肠灌流模型,并通过肠腔有效吸收系数(Peff)、吸收速率常数(Ka)和药物吸收剂量分数(fa)研究不同浓度SRL CS-DCA的肠吸收特性。结果 SRL CS-DCA最优处方:载体浓度(CS-DCA)为10 mg·mL-1,药物与载体质量比为20%,该条件下制备得到的SRL CS-DCA带正电荷(37.0±2.7)mV,粒径(182.2±5.7)nm,包封率>90%,载药量(15.8±0.5)%。SRL CS-DCA经大鼠全肠后,反映药物肠吸收程度的评价指标PeffKafa均较SRL有显著提高(P<0.05);不同浓度的SRL CS-DCA在大鼠全肠段的PeffKafa值无显著性差异,提示胶束在10~100 μg·mL-1吸收无浓度抑制,吸收特征为被动转运的线性动力学过程,推测其可能的吸收机制为被动扩散。结论 SRL制备成聚合物胶束后,对其在大鼠小肠的吸收具有明显的促进作用,从侧面证明SRL CS-DCA能有效改善SRL口服生物利用度。
关键词:  西罗莫司  壳聚糖  聚合物胶束  星点设计-效应面法  在体单向肠灌流
DOI:10.13748/j.cnki.issn1007-7693.2020.08.008
分类号:R944.4
基金项目:浙江省自然科学基金项目(LQY18H300002)
Optimization of Sirolimus Micelles by Response Surface Methodology and Its Effect on Small Intestinal Absorption
CHEN Yan1, ZHANG Yawen2, ZHOU Yunli1, CHEN Xiaoxiao1, WANG Shenghao3, YIN Lina2
1.College of Pharmaceutical Science, Zhejiang Chinese Medical University, Hangzhou 310053, China;2.Institute of Materia Medica, Hangzhou Medical College, Hangzhou 310013, China;3.Zhejiang Peptide Company, Hangzhou 310018, China
Abstract:
OBJECTIVE To prepare sirolimus(SRL) polymer micelles and investigate its effects on the absorption kinetics of rat intestine. METHODS The SRL CS-DCA micelles were prepared by solvent evaporation using deoxycholic acid grafted chitosan(CS-DCA) as carrier. The encapsulation efficiency, drug loading, particle size and potential were taken as the evaluation indexes, and the formulation was optimized by the central composite design-response surface optimization method. In situ single pass perfusion model of rat was set up to investigate intestinal absorption characteristics of SRL CS-DCA micelles with different concentrations. Meanwhile, the intestinal absorption coefficient(Peff), absorption rate constant(Ka) and the dose fraction(fa) were used to evaluate drug absorption. RESULTS The optimum formulation of SRL CS-DCA micelles was as follows:the concentration of CS-DCA was 10 mg·mL-1, and the mass ratio of drug to carrier was 20%. Under this condition, the system had the positive charge of (37.0±2.7)mV, particle size of (182.2±5.7)nm, the encapsulation efficiency greater than 90%, and the drug loading of (15.80±0.5)%. After the SRL CS-DCA micelles passed through the rat intestine, the Peff, Ka and fa were significantly higher than those of SRL(P<0.05). There was no significant difference in the Peff, Ka and fa values of SRL CS-DCA micelles with different concentration in the whole intestine of rats, suggesting that the micelles had no concentration inhibition at 10-100 μg·mL-1, and the absorption characteristics were linear dynamics of passive transport. It was speculated that its possible absorption mechanism was passive diffusion. CONCLUSION The SRL CS-DCA micelles can enhance effect on intestine absorption of SRL monomer, which proves that SRL CS-DCA can effectively improve the oral bioavailability of sirolimus.
Key words:  sirolimus  chitosan  micelle  central composite design-response surface method  in situ single pass perfusion model
扫一扫关注本刊微信